Search clinical trials for: Combination of varlilumab and nivolumab

Total 146516 results

Celldex Therapeutics
Bristol-Myers Squibb

Completed

A Dose Escalation and Cohort Expansion Study of Anti-CD27 (Varlilumab) and Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors

Squamous Cell Carcinoma of the Head and Neck (SCCHN) | Ovarian Carcinoma-Enrollment Completed | Colorectal Cancer (CRC)-Enrollment Completed | Renal Cell Carcinoma (RCC) (Phase ll Only) | Glioblastoma (GBM) (Phase ll Only)-Enrollment Completed

United States
Cascadian Therapeutics Inc.
Celldex Therapeutics

Completed

Study of ONT-10 and Varlilumab to Treat Advanced Ovarian or Breast Cancer

Advanced Breast Carcinoma | Advanced Ovarian Carcinoma

United States
Celldex Therapeutics
Genentech, Inc.

Terminated

A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer

Melanoma | Neoplasms | Neoplasms by Histologic Type | Kidney Neoplasms | Carcinoma, Renal Cell | Urologic Neoplasms | Urogenital Neoplasms | Kidney Diseases | Urologic Diseases | Head and Neck Cancer | Bladder Cancer | Triple Negative Breast Cancer | Non-small Cell Lung Cancer | Clear-cell Metastatic Renal Cell Carcinoma

United States
Parker Institute for Cancer Immunotherapy
Bristol-Myers Squibb; Cancer Research Institute, New York City

Completed

Nivolumab With or Without Ipilimumab in Advanced Metastatic Cancer

Advanced Metastatic Cancer | Advanced Prostate Cancer

United States
Celldex Therapeutics

Terminated

A Study of Varlilumab (Anti-CD27) and Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or IV Melanoma

Unresectable Stage III or Stage IV Melanoma

United States
HUYABIO International, LLC.
Bristol-Myers Squibb

Recruiting

Study Comparing Investigational Drug HBI-8000 Combined With Nivolumab vs. Nivolumab in Patients With Advanced Melanoma

Unresectable or Metastatic Melanoma | Progressive Brain Metastasis

Spain, United States, Italy, Japan, Belgium, France, New Zealand, Brazil, Korea, Republic of, Australia, Germany, Singapore, Czechia, Austria, South Africa, United Kingdom, Puerto Rico
Sidney Kimmel Comprehensive Cancer Center at Johns...
Bristol-Myers Squibb

Active, not recruiting

Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder

Bladder Cancer | Urothelial Carcinoma

United States
Bristol-Myers Squibb

Completed

An Investigational Immuno-therapy Study for Safety of Nivolumab in Combination With Ipilimumab to Treat Advanced Cancers

Lung Cancer

Italy, United States, France, Russian Federation, Spain, Argentina, Belgium, Brazil, Canada, Chile, Czechia, Germany, Greece, Hungary, Mexico, Netherlands, Poland, Romania, Switzerland, Turkey, United Kingdom
Yale University
Bristol-Myers Squibb

Completed

Ipilimumab and Nivolumab in Patients With Anti-PD-1-axis Therapy-resistant Advanced Non-small Cell Lung Cancer.

Carcinoma, Non-Small-Cell Lung

United States
Hospital Universitario Dr. Jose E. Gonzalez

Recruiting

Lowdose Nivolumab in Combination With AVD as Front Line Therapy for Classic Hodgkin's Lymphoma

Safety Issues | Efficacy, Self

Mexico
Yale University
Bristol-Myers Squibb

Active, not recruiting

Ipilimumab and Nivolumab in Recurrent Extensive Stage Small Cell Lung Cancer After Receiving Platinum-based Chemotherapy

Small Cell Lung Cancer

United States
Celleron Therapeutics Ltd.

Unknown

A Trial of CXD101 in Combination With Nivolumab in Patients With Metastatic Microsatellite-Stable Colorectal Cancer (CAROSELL)

Colorectal Neoplasms Malignant

United Kingdom
Compugen Ltd
Bristol-Myers Squibb

Active, not recruiting

COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.

Head and Neck Cancer | Ovarian Cancer | Solid Tumor | Endometrial Neoplasms

United States
HUYABIO International, LLC.

Completed

Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer

Melanoma | Renal Cell Carcinoma | Non-Small Cell Lung Cancer

United States
National University Hospital, Singapore

Recruiting

A Phase I Dose Escalation Study of Selinexor Plus Nivolumab and Ipilimumab in Advanced/Metastatic Solid Malignancies

Metastatic Solid Malignancies | Advance Solid Malignancies

Singapore
Bristol-Myers Squibb

Recruiting

An Observational Study to Evaluate Neoadjuvant Nivolumab (OPDIVO®) in Combination With Platinum-Based Chemotherapy in Non-Metastatic Non-Small Cell Lung Cancer Participants in Germany (NENI)

Resectable Non-small Cell Lung Cancer

Germany
Bristol-Myers Squibb

Recruiting

Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients

Advanced Renal Cell Carcinoma (aRCC)

United States
Clinica Universidad de Navarra, Universidad de...
Highlight Therapeutics

Recruiting

Study of BO-112 With Radiotherapy and Nivolumab for Metastatic Refractory NSCLC (Noelia)

Non-Small Cell Lung Cancer Metastatic

Spain
Zhejiang University

Recruiting

Clinical Study of VG161 in Combination With Nivolumab in Subjects With Advanced Pancreatic Cancer

Advanced Pancreatic Cancer

China
Celldex Therapeutics

Terminated

A Study of Varlilumab (Anti-CD27) and Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma

Neoplasms | Neoplasms by Histologic Type | Kidney Neoplasms | Carcinoma, Renal Cell | Urologic Neoplasms | Urogenital Neoplasms | Kidney Diseases | Urologic Diseases | Clear-cell Metastatic Renal Cell Carcinoma

United States
Yonsei University

Unknown

The Combination of Anti-PD-1 With Radiotherapy in Previously Untreated Metastatic Melanoma

Melanoma

Korea, Republic of
Nektar Therapeutics
Bristol-Myers Squibb

Completed

A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors (PIVOT-02)

Melanoma | Renal Cell Carcinoma | Gastric Cancer | Non Small Cell Lung Cancer | Triple Negative Breast Cancer | Urothelial Carcinoma | HR+/HER2- Breast Cancer

United States, Spain, Canada, France, Italy, Belgium, Poland, United Kingdom
Centre Hospitalier Annecy Genevois
French Lung Cancer Group

Active, not recruiting

Denosumab and Nivolumab Combination as 2d-line Therapy in Stage IV NSC Lung Cancer With Bone Metastases (DENIVOS) (DENIVOS)

Carcinoma, Non-Small-Cell Lung | Bone Metastases

France
AIO-Studien-gGmbH

Completed

Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma Histology (NintNivo)

Adenocarcinoma of the Lung

Germany
Melanoma Institute Australia
Bristol-Myers Squibb

Recruiting

A Phase 2 Clinical Trial of Neoadjuvant Relatlimab and Nivolumab in High Risk, Clinical Stage II Cutaneous Melanoma (Neo ReNi II)

Stage II Melanoma

Australia
Akamis Bio
Bristol-Myers Squibb

Recruiting

Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial Tumours (NEBULA)

Metastatic Cancer | Epithelial Tumor

United States, United Kingdom
NYU Langone Health

Recruiting

Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma

Melanoma | Unresectable Melanoma

United States
Intergruppo Melanoma Italiano

Active, not recruiting

To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib.

BRAF V600 Mutation | Melanoma Metastatic

Italy
Melanoma Institute Australia
Bristol-Myers Squibb

Not yet recruiting

Neoadjuvant Nivolumab and Relatlimab in Cutaneous Squamous Cell Carcinoma

Cutaneous Squamous Cell Carcinoma
Bristol-Myers Squibb

Active, not recruiting

A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma (RELATIVITY-098)

Melanoma

United States, Italy, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czechia, Denmark, Finland, France, Germany, Greece, Israel, Mexico, Norway, Romania, Spain, Sweden, Switzerland, United Kingdom
Institut Claudius Regaud

Completed

TNF-Inhibitor as Immune Checkpoint Inhibitor for Advanced MELanoma (TICIMEL)

Melanoma

France
University of Colorado, Denver
National Comprehensive Cancer Network; Taiho Oncology, Inc.

Recruiting

Oral Decitabine/Cedazuridine (DEC-C) in Combination With Nivolumab for Patients With Mucosal Melanoma

Malignant Melanoma

United States
Celldex Therapeutics

Terminated

A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma

Melanoma

United States
University Hospital Southampton NHS Foundation...
Cancer Research UK; The Christie NHS Foundation Trust; Celldex Therapeutics; Oxford... and other collaborators

Active, not recruiting

A Combination of Rituximab and Varlilumab Immunotherapy in Patients With B-cell Lymphoma (RiVa)

B Cell Lymphoma

United Kingdom
Adaptimmune
GOG Foundation

Recruiting

ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)

Ovarian Cancer

United States, Spain, France, Canada, United Kingdom
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

Plasmablastic Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Refractory High Grade B-Cell... and other conditions

United States
Melanoma Institute Australia
Bristol-Myers Squibb

Recruiting

Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma

Merkel Cell Carcinoma

Australia
GlaxoSmithKline
Iqvia Pty Ltd

Completed

Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo and Sarilumab in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biological Disease-modifying Antirheumatic Drug (DMARDs) and/or Janus Kinase (JAK) Inhibitors (contRAst 3)

Arthritis, Rheumatoid

United States, Germany, Canada, Czechia, Poland, South Africa, Korea, Republic of, Spain, Japan, Argentina, Belgium, Hungary, United Kingdom, Italy, Lithuania
AHS Cancer Control Alberta
Alberta Cancer Foundation

Unknown

Nivolumab Plus Pemetrexed for Head and Neck Squamous Cell Carcinoma (NivoPlus)

SCCHN

Canada
ASST Fatebenefratelli Sacco

Recruiting

Study on the Use of Sarilumab in Patients With COVID-19 Infection

COVID19

Italy
National Institute of Allergy and Infectious Diseases...

Completed

Safety and Efficacy of Subcutaneous Sarilumab in Improving the Quality of Life in People With Indolent Systemic Mastocytosis

Indolent Systemic Mastocytosis

United States
Massachusetts General Hospital
Regeneron Pharmaceuticals

Withdrawn

Study to Assess Sarilumab in Halting Progression of Morphea

Morphea, Plaque Form

United States
Stanford University

Completed

Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis

Sarcoidosis

United States
Universitair Ziekenhuis Brussel

Not yet recruiting

A Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent Glioblastoma (NEO-GLITIPNI)

Recurrent Glioblastoma

Belgium
University of Southern California
National Cancer Institute (NCI)

Recruiting

A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER) (EMPOWER)

Cancer | Metastatic | Breast | Triple Negative | Disseminated Tumor Cell

United States
University of Southern Denmark
Odense University Hospital; Sygehus Lillebaelt; Odense Patient Data Explorative... and other collaborators

Terminated

Interleukin-6 Inhibitors and Drug-drug Interactions in Patients With Rheumatoid Arthritis

Arthritis, Rheumatoid | Interaction

Denmark
Adaptimmune
ICON plc

Recruiting

ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)

Melanoma | Head and Neck Cancer | Esophageal Cancer | Ovarian Cancer | Endometrial Cancer | Urothelial Cancer | Gastric (Stomach) Cancer | Esophagogastric Junction (EGJ) | Non-small Cell Lung (NSCLC)

United States, Canada, Spain, Belgium
Brown University
Bristol-Myers Squibb; The Miriam Hospital; Rhode Island Hospital; Women and Infants...

Terminated

BrUOG 355: Nivolumab to Tailored Radiation Therapy With Concomitant Cisplatin in the Treatment of Patients With Cervical Cancer

Cervical Cancer

United States
Maria del Rosario Garcia de Vicuña Pinedo
Instituto de Investigación Sanitaria Hospital Universitario de la Princesa

Completed

Efficacy of Subcutaneous Sarilumab in Hospitalised Patients With Moderate-severe COVID-19 Infection (SARCOVID) (SARCOVID)

Covid-19

Spain
Kaohsiung Medical University Chung-Ho Memorial...

Completed

Combine Transcranial Direct Current Stimulation and Neuromuscular Electrical Stimulation on Stroke Patients

Stroke

Taiwan

Search clinical trials for: Combination of varlilumab and nivolumab

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ghana

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations